The pharmaceutical industry faces a challenge few industries share: communicating innovation without the message being interpreted as improper advertising. In Mexico, where regulation of health-supply advertising is overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), the difference between informing and promoting can have important regulatory implications.
The challenge is not to stop communicating scientific advances, but to do so with an editorial strategy that prioritizes evidence, education and transparency. Poorly conceived content can lead to regulatory observations, the need to withdraw materials or adjustments to the communication strategy if it fails to comply with the applicable framework.
For laboratories, pharmaceutical communication must build reputation without turning scientific content into a commercial ad.
Informing is not the same as promoting
Mexican regulation distinguishes between scientific information and drug advertising.
COFEPRIS itself establishes that advertising of drugs, medical devices and other health supplies is subject to specific requirements depending on the type of product and the audience it is aimed at. There are even differences between advertising aimed at the general public and that aimed exclusively at healthcare professionals.
That is why, before developing a communication campaign, it is advisable to answer questions such as:
- Does the content have an educational or a commercial purpose?
- Is it aimed at healthcare professionals or the general public?
- Does it describe scientific evidence or encourage use of a specific product?
Answering these questions from the start helps reduce regulatory risks.
Innovation can be communicated without turning the content into advertising
Scientific research offers multiple opportunities to communicate value without centering the message on promoting a drug.
For example, a laboratory can develop content on:
- New advances in biomedical research.
- Challenges of a disease from a public health perspective.
- Innovations in clinical research.
- Processes for developing new treatments.
- Collaborations with research centers.
- Continuing medical education programs.
This type of content strengthens the organization’s scientific leadership without turning every post into a promotional message.
Language also determines how a message is interpreted
Not only the content matters; how it is presented matters too.
In pharmaceutical communication it is advisable to avoid absolute claims, promises of results or messages that could be interpreted as incentives to consume a drug outside the context permitted by regulation.
In contrast, evidence-based communication usually:
- Cites scientific publications where appropriate.
- Explains findings with context.
- Uses objective language.
- Acknowledges the limits of the available evidence.
- Clearly distinguishes institutional information from commercial messages.
This approach strengthens both scientific credibility and regulatory compliance.
Regulatory review must be part of the editorial process
One of the most common mistakes is to check regulatory compliance only when the piece is finished.
However, bringing regulatory and medical teams in from the planning stage can reduce rework and lower the risk of later observations.
COFEPRIS has specific procedures for advertising permits and notices, depending on the type of product and the target audience. Knowing these requirements from the start makes it easier to develop campaigns compatible with the current regulatory framework.
Effective health communication requires collaboration among corporate communication, medical affairs, health regulation and legal teams.
How to communicate pharmaceutical innovation with an editorial approach
1. Talk about the health problem before the product
Explaining the context of a disease or an unmet medical need provides educational value and helps contextualize the innovation.
2. Prioritize scientific evidence
Messages must be backed by studies, peer-reviewed publications or verifiable institutional information.
This strengthens the organization’s credibility.
3. Adapt the content to each audience
Healthcare professionals require technical information different from what the general public needs.
Segmenting messages improves understanding and reduces risks.
4. Integrate regulatory review from the start
Validation of regulatory matters should not be the last step in the editorial process.
Involving the relevant areas from the planning stage favors compliance.
5. Build scientific leadership, not just notoriety
Sustained communication about research, innovation and medical education strengthens corporate reputation far more than posts focused solely on products.
The best pharmaceutical communication is the kind that builds trust
Communicating innovation in the pharmaceutical industry demands much more than turning scientific information into attractive messages.
It also requires understanding the regulatory environment, distinguishing information from promotion and building content that provides real value to healthcare professionals, patients and other stakeholders.
Organizations that integrate editorial strategy, scientific evidence and regulatory compliance strengthen their reputation and reduce risks in an environment where trust is one of the most important assets.
At Altavoz Comunicaciones we help laboratories and healthcare organizations develop editorial strategies that turn scientific evidence into clear, relevant content aligned with the principles of responsible communication and regulatory compliance.
